News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Merck & Co., Inc. Extends Deadline For Talks On Dutch Organon Closures
December 17, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AMSTERDAM Dec 17 (Reuters) - U.S. drugmaker Merck & Co Inc (MRK.N) said on Friday it has further postponed the closure of some of its Dutch operations pending discussions about possible alternatives, including a sale of the R&D site.
Twitter
LinkedIn
Facebook
Email
Print
Real estate
Europe
Merck & Co.
MORE ON THIS TOPIC
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
June 2, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
June 2, 2025
·
3 min read
·
Nick Paul Taylor
Layoff Tracker
Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug
June 2, 2025
·
217 min read
·
BioSpace Editorial Staff
Layoffs
Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval
May 30, 2025
·
2 min read
·
Angela Gabriel